Italfarmaco S.p.A. announced that the U.S. Food and Drug Administration has approved Duvyzat™, a novel histone deacetylase inhibitor, for the treatment of patients 6 years or older with Duchenne muscular dystrophy, a rare X-linked progressive and life-limiting neuromuscular condition with symptoms from early childhood.
